Patent 12110545 was granted and assigned to Editas Medicine on October, 2024 by the United States Patent and Trademark Office.
The present disclosure relates to methods of analyzing activity of nucleases, such as ZFNs, TALENs or CRISPR-associated nucleases, in particular their cutting at “off-target” loci.